Literature DB >> 23755726

Probiotics in the mechanism of protection against gut inflammation and therapy of gastrointestinal disorders.

Katarzyna Dylag, Magdalena Hubalewska-Mazgaj, Marcin Surmiak, Jakub Szmyd, Tomasz Brzozowski1.   

Abstract

A growing body of experimental and clinical evidence supports the hypothesis that the intestinal microbiota markedly influences function and the structure of the mucosal lining. Intestinal microbiota can potentially cause damage to the mucosa either directly by releasing toxins or indirectly by causing a detrimental immune response. Probiotic bacteria have been defined as live microorganisms, which when consumed in adequate amounts, confer a health benefit for the host. In recent years, the therapeutic and preventive application of probiotics for several gastrointestinal and liver disorders has received increasing attention. Probiotics appear to be beneficial for premature infants who suffer necrotizing enterocolitis. The effectiveness of certain probiotics as treatment for infectious and antibioticassociated diarrhea in adults and for allergic disorders in children has been supported by clinical studies; however, the potential mechanism( s) remains to be studied. Experimental studies and clinical trials for probiotic treatment of inflammatory bowel diseases (IBD) have yielded conflicting results. Daily intake of selected probiotics was effective in the prevention of ulcerative colitis and the attenuation of the active onset of Crohn's disease or ulcerative colitis but others failed to show a beneficial effect. The combination of Lactobacillus, Bifidobacterium, Saccharomyces boulardi and the treatment with Escherichia coli Nissle were found beneficial in inducing and maintaining remission of disease activity of gut inflammation and moderately severe ulcerative colitis. Probiotic bacteria were considered in some studies as a safe adjuvant when added to triple eradication therapy against the symptoms induced by the major gastric pathogen, Helicobacter pylori. This review attempted to overview these new exciting advances in the role of these microbes in the pathogenesis, management and treatment of gastrointestinal disorders.

Entities:  

Mesh:

Year:  2014        PMID: 23755726     DOI: 10.2174/13816128113199990422

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  19 in total

1.  Antimicrobial peptides targeting Gram-negative pathogens, produced and delivered by lactic acid bacteria.

Authors:  Katherine Volzing; Juan Borrero; Michael J Sadowsky; Yiannis N Kaznessis
Journal:  ACS Synth Biol       Date:  2013-07-10       Impact factor: 5.110

Review 2.  [Effect of probiotics in prevention and treatment of allergic diseases in children].

Authors:  Li-Ping Xia; Yi Jiang
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2016-02

3.  Topical treatment with probiotic Lactobacillus brevis CD2 inhibits experimental periodontal inflammation and bone loss.

Authors:  T Maekawa; G Hajishengallis
Journal:  J Periodontal Res       Date:  2014-02-01       Impact factor: 4.419

Review 4.  Probiotics for people with hepatic encephalopathy.

Authors:  Rohan Dalal; Richard G McGee; Stephen M Riordan; Angela C Webster
Journal:  Cochrane Database Syst Rev       Date:  2017-02-23

5.  Effects of different probiotic strains B. lactis, L. rhamnosus and L. reuteri on brain-intestinal axis immunomodulation in an endotoxin-induced inflammation.

Authors:  Monique Michels; Gabriel Fernandes Alves Jesus; Mariane Rocha Abatti; Emily Córneo; Luana Cucker; Heloisa de Medeiros Borges; Natan da Silva Matos; Luana Bezerra Rocha; Rodrigo Dias; Carla Sasso Simon; Ana Paula Lorenzen Voytena; Marina Rossetto; Fernanda Ramlov; Felipe Dal-Pizzol
Journal:  Mol Neurobiol       Date:  2022-06-08       Impact factor: 5.682

6.  Escherichia coli Nissle 1917-derived factors reduce cell death and late apoptosis and increase transepithelial electrical resistance in a model of 5-fluorouracil-induced intestinal epithelial cell damage.

Authors:  Hanru Wang; Susan E P Bastian; Ker Y Cheah; Andrew Lawrence; Gordon S Howarth
Journal:  Cancer Biol Ther       Date:  2014-02-20       Impact factor: 4.742

Review 7.  Brain-gut axis in the pathogenesis of Helicobacter pylori infection.

Authors:  Jacek Budzyński; Maria Kłopocka
Journal:  World J Gastroenterol       Date:  2014-05-14       Impact factor: 5.742

Review 8.  Microorganisms with claimed probiotic properties: an overview of recent literature.

Authors:  Sabina Fijan
Journal:  Int J Environ Res Public Health       Date:  2014-05-05       Impact factor: 3.390

Review 9.  Noninfectious Diarrhea in HIV Seropositive Individuals: a Review of Prevalence Rates, Etiology, and Management in the Era of Combination Antiretroviral Therapy.

Authors:  Patrick G Clay; Rustin D Crutchley
Journal:  Infect Dis Ther       Date:  2014-11-12

Review 10.  Luminal Conversion and Immunoregulation by Probiotics.

Authors:  Bhanu Priya Ganesh; James Versalovic
Journal:  Front Pharmacol       Date:  2015-11-12       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.